Related Experiment Videos
Metastatic breast cancer: understanding current management options
Oncology Nursing Forum
|May 8, 2001
Summary
Newer treatments for metastatic breast cancer, including chemotherapy, hormonal therapy, and monoclonal antibodies, offer improved survival and quality of life. Understanding these advanced therapies is crucial for patient care and outcomes.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic breast cancer (MBC) management relies on standard treatments like surgery, radiation, hormonal therapy, and chemotherapy.
- While standard options can prolong survival, they rarely offer a cure for most patients.
Purpose of the Study:
- To review established treatments for MBC.
- To present recently approved chemotherapeutic and hormonal agents.
- To describe novel biologic therapies, focusing on monoclonal antibodies.
Main Methods:
- Review of published articles.
- Analysis of abstracts and conference proceedings.
Main Results:
- New chemotherapeutic agents include paclitaxel, docetaxel, and capecitabine.
- New hormonal agents approved are toremifene, letrozole, and exemestane.
- Trastuzumab, a monoclonal antibody and biologic response modifier (BRM), is a promising new option for a subset of MBC patients.
Conclusions:
- Advanced therapies, including monoclonal antibodies and BRMs, offer hope for extended survival and improved quality of life in MBC.
- Ongoing research is identifying new therapeutic targets for breast cancer.
- Nurses and clinicians must be knowledgeable about newer MBC treatments, patient selection criteria, and managing treatment toxicities for optimal patient outcomes.